July 3, 2024
Orphan Drug Designation for proprietary Factor H therapy in C3G adds significant value to the Factor H (CPV-104) program.
All stories
May 3, 2023
Serial entrepreneur and molecular biologist to lead Eleva into next development phase
Jan 4, 2024
His appointment reflects the growing maturity of Eleva’s proprietary pipeline programs.
May 13, 2024
Data demonstrates the therapeutic potential of Factor H (CPV-104) as complement modulator and delivered preclinical proof-of-concept in C3G.
July 3, 2024
Orphan Drug Designation for proprietary Factor H therapy in C3G adds significant value to the Factor H (CPV-104) program.
Jul 16, 2024
Eleva's bryotechnology revolutionizes biologics manufacturing. Björn talks about the critical roles of perseverance and innovation in the biotech industry.
Back to
